SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors anticipate potential catalysts from the upcoming earnings call, with community chatter focused on a possible buyout or partnership announcement, especially with AstraZeneca, given their aligned earnings release date and recent facilities transaction. Some traders are positioning for a short squeeze due to high short interest and a decrease in available shares to borrow, while others express skepticism and frustration with management's past performance. The broader context involves speculation around the future of COVID-19 vaccines and Novavax's role in the evolving market.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending amid excitement surrounding a new partnership with Perplexity AI, which includes a $400 million deal and integration of AI search into Snapchat. The community is discussing the potential for this deal, combined with a stock buyback program, to signal a turnaround and re-rate the stock, especially given Snap's large user base and AI initiatives. Some traders are anticipating a short squeeze and upgrades from analysts.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is trending as investors anticipate upcoming earnings, with many expecting a positive report driven by strong growth and the Alani Nu acquisition. The community is actively discussing potential price targets and whether the stock will experience a post-earnings surge, while also debating the impact of potential market manipulation. Sentiment remains largely bullish, with some viewing any dips as buying opportunities ahead of earnings.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT) is trending as the community debates its potential amid discussions of buybacks and token unlocks scheduled for February. Some investors express concerns about competitor influence, particularly from $BNB and $ASTER, while others champion $AVNT as a Coinbase-backed project with a live buyback dashboard and locked developer tokens. Traders are watching key price levels, anticipating volatility and potential for a short squeeze.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo ($DUOL) is trending due to a significant after-hours drop following its earnings release, despite reporting a revenue and EPS beat. Community chatter revolves around the disappointing forward guidance and concerns about future growth, leading to debates about valuation and the potential impact of AI on its business model. Some investors view the dip as a buying opportunity, while others express caution amid analyst downgrades.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid is trending as the EV maker announced partnerships with both Uber and Nvidia, generating bullish sentiment. The community is discussing the potential for Lucid to achieve Level 4 autonomous driving and the possibility of a short squeeze. Despite the positive news, concerns remain around profitability, upcoming earnings, and potential dilution.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is trending as investors discuss the company's potential in AI-driven infrastructure and smart city solutions, fueled by significant contracts and growing institutional confidence. Community members highlight the favorable risk-reward asymmetry and upcoming earnings as potential catalysts. Some traders express frustration with recent price action, while others remain optimistic about the long-term prospects and potential acquisition.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy is trending as the community anticipates a potential breakout, emphasizing its long-term potential. Many users are highlighting the ability to earn crypto through walking and staking, though others are wary of the token's price action. Community members are also excited about the US launch of Sweat Wallet.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is trending as investors assess the impact of recent earnings and guidance, with debates focusing on long-term profitability and growth potential. Community members are weighing the company's AI integration and potential for a short squeeze against concerns about valuation and lock-up periods. The stock's performance relative to peers and broader market trends is also a key talking point.

SSgA Active Trust - Financial Select Sector SPDR

Financial Select Sector SPDR Fund

XLF is trending amid discussions about potential breakouts and pullbacks, as well as reaction to bank stress test results. Community members are actively trading options, with bullish and bearish sentiment around the fund's next move. Economic indicators and sector rotation are also influencing conversations around XLF.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's  What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 106.5% in Enliven Therapeutics, Inc. (ELVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know

Enliven Therapeutics, Inc. (ELVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41%

The consensus price target hints at a 102.4% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 75.7% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Short sellers pulled back from Enliven Therapeutics last week, with Ortex data, compiled by The Fly,&nbsp; showing a sharp decline in short interest from 25.7% to 18.4% — the lowest since April 2023.&nbsp;The unwind coincided with a spike in trading volume, triggered by updated Phase 1 results for the company’s chronic myeloid leukemia (CML) candidate ELVN-001 and a bullish initiation from Goldman Sachs.Enliven Therapeutics shares closed at $21.3 on Friday, down 1.3% on the day.Ortex also reported that days to cover, a key metric representing the average number of days it would take shorts to cover their positions at current volume, dropped to 6.9 from 7.8, a nine-month low.&nbsp;The estimated short interest had ranged between 24% and 29% since October 2023.The catalyst was the company’s presentation at the European Hematology Association (EHA) Congress in Milan.&nbsp;Updated data from the ongoing Phase 1 ENABLE trial showed that 25 of 53 evaluable patients without the T315I mutation,&nbsp;or nearly 47%, achieved or maintained major molecular response (MMR) by week 24.&nbsp;The patients in the study were heavily pretreated, with 67% having received three or more prior TKIs.Enliven said ELVN-001 remained well-tolerated across all doses.&nbsp;The drug showed no signs of enhanced cardiovascular risk or arterial occlusive events, with just 3.4% of patients requiring dose reductions due to adverse events and 4.6% discontinuing due to side effects.&nbsp;The drug’s pharmacokinetics support once-daily oral dosing without fasting restrictions and minimal drug-drug interaction, which is a key benefit given&nbsp;that the average CML patient takes about five medications.Additionally, Goldman Sachs initiated coverage on Enliven Therapeutics with a ‘Buy’ rating and a $37 price target, citing positive Phase 1 data for ELVN-001 and plans to start a Phase 3 trial in 2026.&nbsp;The firm said the drug remains well-tolerated, with no added cardiovascular risk, and highlighted its once-daily dosing potential and minimal drug interaction profile.On Stocktwits, retail sentiment was ‘neutral’ amid ‘high’ message volume.The stock has declined 10.9% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’

Ortex data shows short interest in Enliven Therapeutics had hovered between 24% and 29% since October 2023.

Equity

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference PR Newswire BOULDER, Colo., Feb...

Mizuho refreshes its US top picks list for January

Investing.com --  Mizuho  (NYSE:MFG) has updated its US Top Picks list for January, adding Chewy (NYSE:CHWY), GE Vernova (NYSE:GEV), Enliven Therapeutics Inc (NASDAQ:ELVN), Quest Diagnostics (NYSE:DGX), DuPont de Nemours (NYSE:DD), and Salesforce (NYSE:CRM). These selections reflect Mizuho’s highest-conviction ideas driven by catalysts expected to play out over the next 12 months.

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update PR Newswire...

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference Enliven Therapeutics to Present at the Jefferies London Healthcare Conference PR Newswire BOULDER, Colo., Nov. 7, 2024...

FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket PR Newswire VANCOUVER, BC, Oct. 4, 2024 USA News Group...

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

ELVN
Enliven Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ELVN News

ELVNEnliven Therapeutics Inc